AT&T added more than 1 million Advanced Connectivity customers for a second consecutive quarter, driven by net adds across fiber, fixed wireless and postpaid phone

AT&T updates outlook to reflect higher 2026 adjusted EPS* and lower long-term capital investment while remaining on track to reach more than 60 million locations with fiber by end of 2030

DALLAS, Oct. 21, 2026 /PRNewswire/ -- AT&T Inc. (NYSE: T) reported third-quarter results, extending the momentum of its investment-led strategy as it delivers advanced connectivity to more consumers and businesses. The Company achieved a record quarter for Advanced Connectivity internet net adds and grew its base of high-value converged relationships by approximately 350,000. The results demonstrate the value of AT&T's differentiated fiber and 5G portfolio as it continues to accelerate growth in consolidated service revenue and improve operating efficiency, driving durable long-term profitability.

"We are growing valuable customer relationships as more homes and businesses choose AT&T for all their advanced connectivity needs across both internet and on-the-go wireless," said John Stankey, AT&T Chairman and CEO. "Our asset base positions us well for the AI era, with a leading position in fiber – the best technology available. We're building the nation's strongest network, backed by America's Best Guarantee, to deliver faster, more reliable and more accessible connectivity."

Third-Quarter 2026 Consolidated Financial Results1

- Revenues totaled $32.3 billion, up 5.3% year over year

- Diluted EPS from continuing operations was $0.13, which includes a non-cash impairment charge associated with the Company's held-for-sale Mexico wireless business as well as employee separation charges, versus $1.29 in the year-ago quarter, which included a gain recognized on the sale of the DIRECTV investment; adjusted EPS* was $0.65, versus $0.54 in the year-ago quarter

- Operating income was $4.1 billion; adjusted operating income* was $7.6 billion

- Income from continuing operations was $1.3 billion; adjusted EBITDA* was $12.5 billion, up 5.4% year over year

- Cash from operating activities from continuing operations was $10.5 billion, versus $10.2 billion in the year-ago quarter

- Capital expenditures related to continuing operations were $5.1 billion; capital investment* was $5.6 billion

- Free cash flow* was $5.0 billion, versus $4.9 billion in the year-ago quarter

Third-Quarter 2026 Highlights

- Second consecutive quarter with over 1 million Advanced Connectivity customer additions, driven by accelerated internet net adds and solid postpaid phone net adds

- Advanced Connectivity service revenue of $23.9 billion, up 6.1% year over year

- Advanced Connectivity operating income of $7.6 billion, up 18.9% year over year, with EBITDA* of $12.3 billion, up 7.3%

- 42.8% of households with AT&T's advanced home internet services also chose AT&T wireless2

- 769,000 total consumer and business Advanced Connectivity internet net adds, a record quarter, including 442,000 fiber and 327,000 fixed wireless

- 379,000 postpaid phone net adds with postpaid phone churn of 0.92%

- Reached more than 39 million total consumer and business locations with fiber; the Company remains on track to reach over 40 million total fiber locations by the end of 2026 and more than 60 million locations by the end of 20303

- Returned approximately $4.8 billion to shareholders, including $2.8 billion in common share repurchases

Financial Outlook and Capital Allocation Plan

AT&T is increasing its outlook for 2026 adjusted EPS* and lowering its long-term outlook for capital investment. AT&T maintains its long-term outlook for improved growth in adjusted EBITDA* and adjusted EPS* and higher free cash flow* through 2028, its plans to return $45 billion+ to shareholders during 2026-2028 through dividends and share repurchases, and an expectation that its net debt-to-adjusted EBITDA ratio* will return to a level consistent with its target in the 2.5x range during 2029.

AT&T's long-term outlook is presented on a continuing operations basis and, for 2027-2028, excludes AT&T Mexico, which it has agreed to sell to Grupo Televisa and Fintech Holdings.

The Company's long-term outlook for 2026-2028 includes4:

- Service revenue growth in the low-single-digit range annually

- Advanced Connectivity service revenue growth in the mid-single-digit range annually, including expected growth of 5%+ in 2026

- Legacy service revenue decline of 20%+ in 2026 and be immaterial by the end of 2029

- Adjusted EBITDA* growth in the upper portion of the 3% to 4% range in 2026, improving to 5% or better in 2028

- Advanced Connectivity EBITDA* growth in the mid-to-high-single-digit range annually, including expected growth of 6%+ in 2026

- Legacy EBITDA* expected to turn negative after 2027, until AT&T has substantially eliminated direct costs associated with operating its copper-based network5

- Adjusted EPS* in the $2.40 range in 2026 with a double-digit 3-year CAGR through 2028

- Capital investment* in the $23 billion to $24 billion range in 2026 and in the $22 billion to $23 billion range annually in 2027 and 2028

- Free cash flow* of $18 billion+ in 2026, $19 billion+ in 2027, and $21 billion+ in 2028

- Strong capital returns, including plans to maintain its current annualized common stock dividend of $1.11 per share and $24 billion+ of share repurchases, including approximately $10 billion during 2026

Note: AT&T's third-quarter 2026 earnings conference call will be webcast at 8:30 a.m. ET on Wednesday, October 21, 2026. The webcast and related materials, including financial highlights, will be available at investors.att.com.

Detailed Third-Quarter 2026 Consolidated Financial Results

- Revenues for the third quarter totaled $32.3 billion, versus $30.7 billion in the year-ago quarter, up 5.3%. This was largely due to growth in Advanced Connectivity wireless service and equipment revenues, and fiber revenues, which include the impact of the Company's first-quarter acquisition of Lumen's mass markets fiber business. Operating revenues in Latin America were also higher due to favorable foreign exchange impacts and growth in postpaid revenues. Offsetting the increases were lower Legacy revenues from lower demand for services as the Company continues to decommission its copper-based network.

- Operating expenses were $28.2 billion, versus $24.6 billion in the year-ago quarter. Operating expenses increased primarily due to a non-cash impairment charge associated with the Company's held-for-sale Mexico wireless business of $2.6 billion, employee separation charges, increased wireless equipment costs, as well as higher advertising and higher bad debt expenses driven by subscriber growth. The increase was also due to incremental customer costs related to the acquired mass markets fiber business. These increases were partially offset by cost reductions from transformation initiatives and apportioned legal settlements in the prior-year period. Depreciation expense was also lower year over year from fully depreciated legacy assets, partially offset by ongoing capital spending for strategic initiatives.

- Operating income was $4.1 billion, versus $6.1 billion in the year-ago quarter. Adjusted operating income* was $7.6 billion, versus $6.6 billion in the year-ago quarter.

- Income from continuing operations was $1.3 billion, versus $9.7 billion in the year-ago quarter.

- Income from continuing operations attributable to common stock was $0.9 billion, versus $9.3 billion in the year-ago quarter. Earnings per diluted common share from continuing operations was $0.13, versus $1.29 in the year-ago quarter, which included a gain recognized on the sale of the DIRECTV investment. Adjusting for $0.52, which includes a non-cash impairment charge associated with the held-for-sale Mexico wireless business, employee separation charges, and other items, adjusted earnings per diluted common share* was $0.65, versus $0.54 in the year-ago quarter.

- Adjusted EBITDA* was $12.5 billion, versus $11.9 billion in the year-ago quarter.

- Cash from operating activities from continuing operations was $10.5 billion, versus $10.2 billion in the year-ago quarter, which included voluntary pension plan contributions. The increase also reflects timing of working capital payments.

- Capital expenditures related to continuing operations were $5.1 billion, versus $4.9 billion in the year-ago quarter. Capital investment* totaled $5.6 billion, versus $5.3 billion in the year-ago quarter. Cash payments for vendor financing totaled $0.5 billion, versus $0.4 billion in the year-ago quarter.

- Free cash flow* was $5.0 billion, versus $4.9 billion in the year-ago quarter.

- Total debt was $159.6 billion at the end of the third quarter and net debt* was $149.8 billion, both reflecting a sequential increase related to the closing of the EchoStar spectrum transaction.

AT&T Third-Quarter 2026 Segment Results6

Advanced Connectivity service revenues grew 6.1% year over year, driving growth in operating income of 18.9% and EBITDA* of 7.3%. Internet net adds were 769,000 – comprised of 442,000 fiber and 327,000 fixed wireless – and postpaid phone net adds were 379,000.

Advanced Connectivity segment revenues grew 7.2% year over year, driven by service revenue growth of 6.1% and higher equipment revenue. Wireless service revenue increased due to growth in retail wireless subscribers in underpenetrated categories and converged accounts, and pricing actions that were partially offset by promotional discounts on wireless subscriber additions. Advanced home internet revenue growth, which included an impact from the acquired mass markets fiber business that closed in the first quarter, reflects increases in fiber and AT&T Internet Air revenues. Business fiber and advanced connectivity revenues increased largely due to higher fiber and fixed wireless revenues.

RACINE, Wis., Oct. 21, 2026 /PRNewswire/ -- Modine (NYSE: MOD), a diversified global leader in thermal management technology and solutions, announced today that it will host a conference call and webcast to discuss its second quarter fiscal year 2027 financial results for the period ended September 30, 2026, on Wednesday, November 4, 2026, at 10:00 a.m. Central Time (11:00 a.m. Eastern Time). Results are scheduled to be released after the market closes on Tuesday, November 3, 2026.

During the call, Modine President and Chief Executive Officer, Neil D. Brinker, and Executive Vice President and Chief Financial Officer, Michael B. (Mick) Lucareli, will review the company's second quarter financial results.

To access the live webcast, including presentation slides, please log on through the investor section of Modine's website at http://www.modine.com at least 10 minutes prior to the start of the event. A replay of the slides and the audio will be available on or after November 4, 2026, on the investor section of Modine's website at http://www.modine.com. An audio only replay will be available through midnight on November 11, 2026, by dialing 877-660-6853 (international replay 201-612-7415) and entering the Conference ID# 13762536. A transcript of the call will be posted to the company's website on or after November 9, 2026.

About Modine

For more than 100 years, Modine has solved the toughest thermal management challenges for mission-critical applications. Our purpose of Engineering a Cleaner, Healthier World™ means we are always evolving our portfolio of technologies to provide the latest heating, cooling, and ventilation solutions. Through the hard work of more than 9,000 employees worldwide, our businesses advance our purpose with systems that improve air quality, reduce energy and water consumption, and use environmentally friendly refrigerants. Modine is a global company headquartered in Racine, Wisconsin (U.S.), with operations in North America, Europe, and Asia. For more information about Modine, visit www.modine.com.

Contact: Kathleen Powers (262) 636-1687 [email protected]

SOURCE Modine

Share this article

TORONTO, Oct. 21, 2026 /PRNewswire/ -- Auxly Cannabis Group Inc. (TSX: XLY) (OTCQB: CBWTF) ("Auxly" or the "Company") will be presenting at Planet MicroCap Toronto 2026 powered by MicroCapClub on Wednesday, October 28, 2026 at 10:30 AM EST at the Arcadian Court & Loft in Toronto. Hugo Alves, Auxly's Chief Executive Officer, will be hosting the presentation.

To access the live presentation, please use the following information:

Planet MicroCap Toronto 2026 Powered by MicroCapClub

Date: Wednesday, October 28, 2026

Time: 10:30 AM (Toronto Local Time EST)

Webcast: LINK

If you would like to book 1x1 investor meetings with Auxly and to attend the Planet MicroCap Toronto 2026, please make sure you are registered here: REGISTER. Meetings will be scheduled and conducted in person at the conference venue.

The Planet MicroCap Toronto 2026 website is available here: HOME PAGE

If you can't make the live presentation, all company presentations "webcasts" will be available directly on the conference event platform on this link under the tab "Agenda": AGENDA

About Auxly Cannabis Group Inc.

Auxly is a leading Canadian consumer packaged goods company in the cannabis products market, headquartered in Toronto, Canada. Our mission is to help consumers live happier lives through quality cannabis products that they trust and love.

Our vision is to be a leader in branded cannabis products that deliver on our consumer promise of quality, safety and efficacy.

Learn more at www.auxly.com and stay up to date at X (Twitter): @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Auxly Cannabis Group Inc.

Share this article

RTX's Pratt & Whitney Canada introduces certified PT9 engine

New centerline turboprop delivers more power, efficiency and flexibility for next-generation aircraft

LAS VEGAS, Oct. 21, 2026 /PRNewswire/ -- Pratt & Whitney Canada today unveiled its latest turboprop engine with a new centerline that delivers 33% more power at altitude and reduces fuel consumption by 20%, compared to previous generation engines. The engine, which amassed more than 14,000 development hours, was recently certified by Transport Canada. Pratt & Whitney is an RTX (NYSE: RTX) business.

"The PT9 engine represents the next evolution of turboprop propulsion, delivering significant advances in performance, efficiency and adaptability to meet the needs of modern aviation," said Satheeshkumar Kumarasingam, president, Pratt & Whitney Canada. "Designed around evolving customer needs, including advanced digital capabilities and future-ready hybridization, its architecture can be tailored to diverse airframe types and provides a strong foundation for continued innovation and technology integration."

The PT9 engine combines jet-like performance, turboprop efficiency and advanced digital intelligence in a next-generation architecture designed to provide more capability today and evolve with the aircraft of tomorrow. Its modular construction sets the foundation for continued innovation and technology integration, including electric aircraft and hybrid thermal-electric powerplants. The PT9 engine is ideal for high-demand missions and can be easily tailored to diverse airframe types.

Production will take place in Lethbridge, Alberta, Canada, which is also the company's global Center of Excellence for the PT6 family of turboprop engines.

About Pratt & Whitney  

Pratt & Whitney, an RTX business, is a world leader in the design, manufacture and service of aircraft engines and auxiliary power units for military, commercial and civil aviation customers. Since 1925, our engineers have pioneered the development of revolutionary aircraft propulsion technologies, and today we support more than 90,000 in-service engines through our global network of maintenance, repair and overhaul facilities.

About RTX 

With more than 180,000 global employees, we push the limits of technology and science to redefine how we connect and protect our world. With industry-leading capabilities, we advance aviation, engineer integrated defense systems for operational success, and develop next-generation technology solutions and manufacturing to help global customers address their most critical challenges. The company, with 2025 sales of more than $88 billion, is headquartered in Arlington, Virginia.  

For questions or to schedule an interview, please contact [email protected].

SOURCE RTX

Share this article

BURLINGTON, N.C., Oct. 21, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on December 11, 2026, to stockholders of record as of the close of business on November 24, 2026.

About Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

SOURCE Labcorp Holdings Inc

Share this article

– New Phase 2 CALLIPER Open-Label Extension Data Support Durability of Disability Outcomes Observed During the Double-Blind Period With Continued Vidofludimus Calcium Treatment; Safety and Tolerability Profile Appeared Consistent With That Observed in the Double-Blind Period –

– New Preclinical Data Suggest Nurr1-Dependent Neuronal Survival and Neuroprotective Effects Beyond DHODH Inhibition –

– Exploratory and Post-hoc CALLIPER Analyses Show Significant Reductions in EBV-Specific T-Cell Receptor Signatures; Observed Reductions Associated With Increased Symbol Digit Modalities Test (SDMT) Scores –

– Post-hoc Analysis of CALLIPER Using a Proposed Novel Disability Measure Suggests Overall Benefit of Vidofludimus Calcium in Progressive Multiple Sclerosis Patients –

NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that new clinical, biomarker, and preclinical data for its lead investigational asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), are being presented across four poster presentations at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting, taking place October 21-23, 2026, in Toronto. All posters are available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations. Additionally, the team is available throughout the event at booth #516.

"The data presented at MSToronto2026 provide complementary clinical and mechanistic evidence supporting the differentiated profile of vidofludimus calcium across the multiple sclerosis (MS) spectrum," said Erik Lundgren, Chief Executive Officer of Immunic. "Importantly, the new CALLIPER open-label extension (OLE) analyses provide favorable long-term follow-up of the disability signals observed during the double-blind treatment period, while the Nurr1, Epstein-Barr virus (EBV), and disability endpoint analyses provide additional insight into the biology of disease progression and how treatment effects may be more comprehensively measured. Together, these findings further support the clinical and scientific rationale for our planned Phase 3 program in progressive MS, which we expect to initiate later this year, while we also approach the top-line results from our fully enrolled Phase 3 ENSURE trials in relapsing MS, expected by year-end 2026."

New Phase 2 CALLIPER Open-Label Extension Data Support Durability of Disability Outcomes

Poster Title: Evaluation of Disability Outcomes from the Open-Label Extension of CALLIPER: A Phase 2 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

- Lead Author: Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio and Coordinating Investigator of the CALLIPER trial

- Presentation: Paper Poster, Poster Number P0387

- Date and Time: Poster Session 1, Wednesday, October 21, 2026, 4:30 - 6:30 pm ET

New analyses of the Phase 2 CALLIPER trial showed that the favorable trends on disability outcomes observed during the double-blind main treatment period were maintained during the OLE phase among participants who continued vidofludimus calcium treatment. Only 6.5% of patients discontinued through the January 27, 2026 data cutoff, with a safety and tolerability profile that appeared consistent with that observed in the double-blind period.

Preclinical Models Suggest Nurr1-Dependent Neuronal Survival and Neuroprotective Effects

Poster Title: Vidofludimus Calcium Requires Nurr1 to Promote Neuronal Survival In Vitro and Is Associated with Neuroprotective Effects in Murine Models of Multiple Sclerosis

- Lead Author: Mehrnoosh Jafari, Senior Manager Translational Pharmacology at Immunic

- Presentation: Paper Poster, Poster Number P1273

- Date and Time: Poster Session 2, Thursday, October 22, 2026, 4:30-6:30 pm ET

New preclinical findings across multiple models suggest that vidofludimus calcium promotes neuronal survival under apoptotic stress conditions, an effect requiring Nurr1, and in addition reduces microglia-driven neuronal loss, supporting direct and indirect neuroprotective mechanisms. Under in vitro apoptotic conditions, vidofludimus calcium promoted neuronal survival, an effect not observed with teriflunomide, suggesting that the observed pro-survival effect involves mechanisms beyond DHODH inhibition.

Vidofludimus calcium also reduced disease severity and plasma neurofilament light (NfL) chain levels in murine experimental autoimmune encephalomyelitis (EAE) models, and increased brain-derived neurotrophic factor (BDNF) levels and expression of Nurr1-regulated target genes, providing additional evidence consistent with activation of Nurr1-pathways.

Taken together, these findings provide further preclinical evidence of the profile of vidofludimus calcium on pathways associated with neuroprotective effects.

Exploratory and Post-hoc CALLIPER Analyses Link Reduced EBV-Specific T-Cell Signatures with Improved Cognitive Performance as Measured by the Symbol Digit Modalities Test

Poster Title: Anti-EBV T-cell Receptor Repertoire Reduction Is Linked to Enhanced Cognitive Performance in Progressive Multiple Sclerosis: Evidence from the Phase 2 CALLIPER Trial with Vidofludimus Calcium, a Direct Nurr1 Activator and Selective DHODH Inhibitor

- Lead Author: Amelie Schreieck, Ph.D., Senior Manager Biomarker Development at Immunic

- Presentation: ePoster, Number EP2473

- Date and Time: ePoster screens within the congress center and on the congress platform for the duration of the congress

An exploratory CALLIPER analysis found that vidofludimus calcium significantly reduced EBV-specific TCRβ chain (TRB) sequence matches versus placebo-treated patients (-0.65 matches; p=0.0004), while influenza A-specific matches were unchanged (+0.08; p=0.5983), suggesting an EBV-selective rather than generalized effect on the T-cell repertoire, consistent with a lowered rate of EBV reactivations. Across all patients, reductions in EBV-specific TRB matches were associated with improved Symbol Digit Modalities Test (SDMT, broadly used to assess processing speed) scores, as assessed in a post-hoc analysis. Safety and tolerability data from the CALLIPER trial are summarized below.

These exploratory findings support further investigation of the relationship between EBV-related immune activity and cognitive function in progressive MS.

Novel CALLIPER Analyses Evaluate Disability Improvement and Worsening Together

Poster Title: Bidirectional Disability Changes in Progressive Multiple Sclerosis Patients: a Proposed Endpoint to Capture Full Treatment Effects

- Lead Author: James Myles, Global Head of Biostatistics at Immunic

- Presentation: ePoster, Number EP2205

- Date and Time: ePoster screens within the congress center and on the congress platform for the duration of the congress

Traditional progressive MS analyses have focused primarily on delaying confirmed disability worsening, with improvement often not captured fully or assessed separately. This analysis evaluates two novel statistical models, Confirmed Disability Change (CDC) and Generalized Pairwise Comparisons (GPC), as proposed methods to integrate confirmed disability worsening and improvement into a single statistical analysis measure.

Applying both methods to CALLIPER post-hoc, progressive MS patients treated with vidofludimus calcium appeared more likely to have positive outcomes as compared to placebo, suggesting these methods may capture the true bidirectional disability trajectory of patients. The CDC method fits an ordinal logistic regression model to three ordered categories of confirmed disability change. Using data from the CALLIPER trial, patients treated with vidofludimus calcium were 2.47 times more likely to experience 24-week confirmed disability improvement (CDI) (nominal p=0.037), and a positive CDC (nominal p=0.042). The GPC method compares all pairs of patients to determine which patient had a better outcome as measured by improvement, stability, or slowed worsening on the Expanded Disability Status Scale (EDSS) score. By this method, patients on vidofludimus calcium were 1.5 times more likely to have a better outcome than those who received placebo, a statistically significant and clinically meaningful result (p=0.042).

These outcomes support further evaluation of a bidirectional endpoint designed to capture treatment effects across both disability worsening and improvement.

About Vidofludimus Calcium (IMU-838) and the CALLIPER Trial

Vidofludimus calcium (IMU-838) is an investigational oral small molecule activating nuclear receptor-related 1 (Nurr1) and selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). It is currently being evaluated in the Phase 3 ENSURE trials in relapsing multiple sclerosis (MS). More than 3,500 individuals have been exposed to vidofludimus calcium, to date.

The Phase 2 CALLIPER trial randomized 467 patients with primary or secondary progressive MS 1:1 to 45 mg once-daily vidofludimus calcium or placebo. While the primary endpoint of percent brain volume change (PBVC) was not met, exploratory imaging and clinical outcomes showed directionally favorable signals. Rates of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) were similar to placebo (69.4% vs. 68.5% and 8.1% vs. 6.5%, respectively), with no new safety signals and no Hy's law range cases observed. Among the 387 participants who entered the OLE phase, 44.4% experienced at least one TEAE, including 5.7% who experienced a serious TEAE. Liver-related TEAEs occurred in 3.1% of participants, and TEAEs leading to discontinuation in 1.8%.

Vidofludimus calcium (IMU-838) is an investigational medicinal product that has not been approved or authorized by the U.S.

Collaborators publish new peer-reviewed study identifying sex-specific effects of TUSC2 loss on mitochondrial function, protein homeostasis, and synaptic pathways, alongside molecular similarities with human brain

Findings suggest that TUSC2 may play a foundational role in brain health

AUSTIN, Texas, Oct. 21, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, today highlighted new peer-reviewed research in mice identifying an important role for the TUSC2 tumor suppressor gene in maintaining cellular processes associated with healthy brain aging and supporting broader understanding of how disruption of normal biological function may contribute to disease.

The study, entitled "Mitochondrial calcium sensor TUSC2 protects the aging hippocampus from proteostasis collapse in a sex-specific manner," was published in Mechanisms of Ageing and Development by researchers at Meharry Medical College. TUSC2 is the therapeutic gene used in Genprex's investigational REQORSA® gene therapy, which is being developed for the treatment of cancer.

The research found that loss of TUSC2 in mice was associated with substantial disruption of mitochondrial function, of protein homeostasis and of pathways involved in neuronal communication within the hippocampus, a region of the brain essential for learning and memory. These effects were markedly more pronounced in male mice than in females, suggesting important sex-specific differences in the biological response to TUSC2 deficiency.

Importantly, the researchers also analyzed existing human gene-expression datasets and found that TUSC2 expression declined significantly with age in 11 of 13 examined brain regions, with additional reductions observed in Alzheimer's disease datasets. Levels of TUSC2 protein in the hippocampus, as in the rest of the brain, decrease as humans age. Comparisons between the mouse findings and human hippocampal aging datasets identified overlapping molecular changes, supporting further investigation of TUSC2's role in brain aging.

While the research did not evaluate REQORSA as a treatment for aging or neurodegenerative disease, the findings expand scientific understanding of the biological functions of TUSC2, the gene underlying Genprex's lead oncology program.

"This research adds to our understanding of the diverse biological functions of TUSC2, the tumor suppressor gene at the center of our REQORSA oncology program," said Mark Berger, Chief Medical Officer of Genprex. "The findings highlight the important role TUSC2 plays in mitochondrial function, cellular stress responses, and protein homeostasis, while revealing intriguing differences between males and females. Importantly, the parallels identified between the preclinical findings and human brain aging data further reinforce the biological significance of TUSC2 beyond its established role in cancer. While these findings are exploratory, they contribute to a growing body of research into the broader functions of this important gene."

The research utilized an engineered mouse TUSC2 knockout (KO) model to investigate how the loss of TUSC2 accelerates molecular changes associated with hippocampal aging, before the onset of overt neurodegeneration. The findings establish the TUSC2 KO model as a valuable tool for investigating early stages of mitochondrial dysfunction, impaired protein homeostasis, and age-related changes in brain function.

Key study highlights:

- Sex-Specific Resilience: The study identified marked differences in mitochondrial stress resilience between male and female mice. While TUSC2 loss in males disrupted mitochondrial, protein homeostasis and synaptic pathways, females exhibited adaptive cellular stress responses, suggesting greater resilience to TUSC2 deficiency.

- Protein Homeostasis: TUSC2 deficiency was associated with impaired protein quality-control pathways and a significant increase in protein aggregate size in the male hippocampus, supporting a role for TUSC2 in maintaining cellular protein homeostasis.

- Synaptic Pathway Maintenance: The researchers identified substantial disruption of pathways involved in neuronal communication and synaptic function including differences between gene expression and corresponding protein levels, suggesting that TUSC2 contributes to the maintenance of normal synaptic processes.

These findings further support the importance of understanding how biological functions are disrupted in aging and how restoring TUSC2 may open new avenues for therapeutic intervention in age-related cognitive disorders.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focusing on developing innovative treatments designed to restore biological functions disrupted by disease. The Company's lead oncology program, REQORSA® Gene Therapy, is being developed for the treatment of lung cancer and is designed to deliver the TUSC2 tumor suppressor gene to help restore tumor-suppressive activity and address multiple pathways involved in cancer progression.

Genprex is also advancing an earlier stage gene therapy program for diabetes, designed to restore insulin-producing capability through the expression of key pancreatic transcription factors. Across its programs, Genprex is focused on translating innovative gene therapy approaches into meaningful therapeutic advances for patients with significant unmet medical needs.

For more information, please visit https://www.genprex.com/, register for our Email Alerts and follow us on LinkedIn, X, and Facebook.

Cautionary Language Concerning Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2025.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials, its intended regulatory submissions and any resulting regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; Genprex's intellectual property and licenses; and Genprex's current expectations, estimates, forecasts and projections about the industry and markets in which it operates.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Contacts:

Genprex, Inc.

(877) 774-GNPX (4679)

GNPX Investor Relations Contact

Lisa DeScenza

[email protected] 

GNPX Media Contact

Kalyn Dabbs

[email protected] 

SOURCE Genprex, Inc.

Share this article

Property ID Introduces NakedHouse.ai, Bringing Property Entitlements Into the Real Estate Transaction

A new report puts expansion and building potential, additional housing, and allowable uses in buyers' and listing agents' hands.

LOS ANGELES, Oct. 21, 2026 /PRNewswire/ -- What can a buyer actually do with a property? The answer often extends well beyond the home described in a listing—and finding it has traditionally required lengthy research, visits to government offices, and a working knowledge of zoning regulations.

Property ID is introducing Entitlements Home Disclosure through NakedHouse.ai to bring that information into the real estate transaction at the time of listing.

The report examines allowable expansion, additional accessory dwelling units, building-height limits, setbacks, and permitted uses. These details can materially affect how buyers evaluate a property, yet they are often missing from the information available when a purchase decision begins.

Among the least understood are the uses a residential property may accommodate beyond a family home. Depending on applicable rules, these may include home-based businesses, family childcare, and other income-producing activities. Qualifying business uses may also carry tax benefits, depending on the activity and the owner's circumstances.

For a buyer, those possibilities can change the calculation: room for an extended family, an additional income source, space to operate a business, or the ability to expand rather than move.

For a listing agent, they provide a fuller account of what is being offered. The existing house is visible. The rights attached to the land often are not.

NakedHouse.ai brings these findings into one report, showing value that the existing home alone may not convey. In some cases, the right to expand, add housing, or accommodate other uses may be worth more than the structure itself, giving agents a compelling basis for presenting the property's full potential.

About Property ID Corporation

Celebrating 50 years in business, Property ID Corporation is a nationally recognized provider of real estate disclosure and property information services, with nationwide coverage. Supported by an extensive natural hazard database and a dedicated in-house research facility, the company combines decades of expertise, advanced technology, and experienced customer support to deliver critical information to real estate professionals and consumers.

"Press Release Service" should be linked to https://www.24-7pressrelease.com/.

SOURCE Property ID Corporation

Share this article

VANCOUVER, BC, Oct. 21, 2026 /PRNewswire/ -- Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) ("Trilogy Metals", "Trilogy" or the "Company") announced today the successful completion of the 2026 summer field program at the Upper Kobuk Mineral Projects ("UKMP") in northwestern Alaska's Ambler Mining District, with all priority objectives for the season achieved.

Highlights

- 2026 Field Program Completed with All 42 Planned Geotechnical, Hydrogeological, Condemnation and Exploration Holes Drilled Over Approximately 5,200 Meters

- Target Assessments and Advanced Mapping Completed for District-Wide Exploration Drilling Along 100-Kilometer Volcanogenic Massive Sulfide ("VMS") Belt

- David Thomas Appointed Senior Vice President of Project Development of Ambler Metals to Lead Engineering and Development of the Arctic Project

The UKMP asset portfolio, which encompasses approximately 190,929 hectares and hosts both the high-grade Arctic polymetallic deposit (the "Arctic Project" or "Arctic") and the Bornite copper-cobalt deposit (the "Bornite Project" or "Bornite"), is being advanced by Ambler Metals LLC ("Ambler Metals"). Ambler Metals is a 50/50 joint venture operating company equally owned by Trilogy and South32 Limited (ASX, LSE, JSE: S32; ADR: SOUHY) ("South32"). Arctic is one of the highest-grade, undeveloped open-pittable copper deposits in the world, with an estimated average grade of approximately 5% copper equivalent1,2, bolstered by material precious metals by-product credits.

Tony Giardini, President and CEO of Trilogy, commented: "Delivering the full scope of this season's work safely, with every priority objective met, is a credit to the Ambler Metals team. This summer's program gives our engineers the geotechnical and hydrogeological data they need to finalize Arctic's mine design and infrastructure placement, and it strengthens the technical record supporting our permit applications. We anticipate 2027 being a significant step up in activity: exploration and development drilling at Bornite and along the VMS belt, continued engineering at Arctic, and a Draft Environmental Impact Statement targeted for October 2027. With Dave Thomas now leading project development, the joint venture is positioning Arctic for a potential construction decision following a Record of Decision, targeted for September 2028."

Ambler Metals Concludes 2026 Field Program

Ambler Metals has completed all planned geotechnical, hydrogeological, condemnation and exploration holes for the 2026 season – a total of 42 holes across approximately 5,200 meters of drilling – achieving all priority objectives set for the program. The drill campaign, concentrated at the proposed Arctic mine's waste rock storage facilities and tailings footprint areas, and important groundwater characterization targets, was designed to inform mine design and infrastructure placement and to support the permitting process, while also probing exploration targets along the Arctic mineral horizon.

Regional Exploration: Target Assessments Completed Along the 100-Kilometer VMS Belt

Alongside the Arctic drill program, Ambler Metals completed drill-target assessments of known mineral occurrences and targets across the UKMP mineral belt, achieving another key objective of the 2026 season. The 100-kilometer-long (60-mile-long) VMS belt, which hosts Arctic and numerous other polymetallic mineral deposits and prospects, contains approximately 30 known, historic VMS occurrences and electromagnetic anomalies (see Figure 1). The results of these assessments will be used to rank and prioritize targets, and are expected to underpin planning for accelerated exploration and development drilling in 2027.

Project staff are now focused on preparing for the 2027 field season, including completing equipment maintenance and repairs to support an efficient restart of field operations in April/May 2027.

David Thomas Appointed Senior Vice President of Project Development of Ambler Metals

Ambler Metals has appointed David Thomas as Senior Vice President of Project Development. Mr. Thomas will lead engineering and project development for the Arctic Project, working alongside Ambler Metals President Ron Rimelman as the joint venture advances the project through permitting and toward a construction decision.

Mr. Thomas is a civil engineer with more than 40 years of experience in underground and open-pit mining across North America and internationally, including expertise in Arctic developments. His work spans mine complex design, permitting, project development, start-ups, operations, and closure. He most recently served as Chief Operating Officer of Freedom Copper and, prior to that, as Vice President of Ausenco USA, where he provided engineering oversight for preliminary economic assessments, pre-feasibility studies, and feasibility studies for mining projects in Alaska and across the United States. He has also held senior roles with New Mexico Copper and Sabre Gold, and has been involved in mine permitting in Alaska, Washington, Arizona, Utah, and New Mexico. His Alaska experience includes work at the Red Dog, Fort Knox, Pogo, and Kensington mines during his tenure as President of Alaska Interstate Construction. Internationally, Mr. Thomas served as General Director for Nordgold, working on projects in Siberia and Africa, and as EPCM Manager for Newmont's Hope Bay project in Nunavut, Canada. He holds a Bachelor of Science from the University of Washington.

Ron Rimelman, President of Ambler Metals, commented: "As the Arctic Project advances through permitting, our focus is shifting from defining the project to preparing to build it, and Dave brings the expertise we need at this stage. He has spent four decades designing, permitting, building and operating mines – including Arctic developments and, here in Alaska, operations such as Red Dog, Fort Knox, Pogo and Kensington. His engineering leadership on feasibility-level studies, combined with his hands-on construction and start-up experience, will be invaluable as we translate this season's engineering data into final mine design and lay the groundwork for development. We are delighted to welcome him to the Ambler Metals team."

Qualified Persons

Richard Gosse, P.Geo., Vice President Exploration for Trilogy Metals Inc., is a Qualified Person as defined by National Instrument 43-101 – Standard of Disclosure for Mineral Projects and Subpart 1300 of Regulation S-K. Mr. Gosse has reviewed the technical information in this news release and approves the disclosure contained herein.

About Trilogy Metals

Trilogy Metals Inc. is a metal exploration and development company holding a 50 percent interest in Ambler Metals LLC, which has a 100 percent interest in the Upper Kobuk Mineral Projects ("UKMP") in northwestern Alaska. On December 19, 2019, South32 Limited, a globally diversified mining and metals company, exercised its option to form a 50/50 joint venture with Trilogy Metals. The UKMP is located within the Ambler Mining District which is one of the richest and most-prospective known copper-dominant districts in the world. It hosts polymetallic volcanogenic massive sulfide ("VMS") deposits that contain copper, zinc, lead, gold and silver, and carbonate replacement deposits which have been found to host high-grade copper and cobalt mineralization. Exploration efforts have been focused on two deposits in the Ambler Mining District – the Arctic VMS deposit and the Bornite carbonate replacement deposit. Both deposits are located within a land package that spans approximately 190,929 hectares. Ambler Metals has an agreement with NANA Regional Corporation, Inc., an Alaska Native Corporation, that provides a framework for the exploration and potential development of the Ambler Mining District in cooperation with local communities. Trilogy Metals' vision is to develop the Ambler Mining District into a premier North American copper producer while protecting and respecting subsistence livelihoods.

Cautionary Note Regarding Forward-Looking Statements

This news release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, including, without limitation, statements regarding the results of the 2026 field program; expected preparations for, and the timing of, the 2027 field season; expected exploration and development decisions at Bornite and Arctic; expected progress on the permitting process; timing of a draft Environmental Impact Statement and Record of Decision; the anticipated benefits of recent management appointments at Ambler Metals; expectations regarding a construction decision on the Arctic Project; and perceived merit of the properties are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.

DELRAY BEACH, Fla., Oct. 21, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the microencapsulation market is projected to grow from USD 16.90 billion in 2026 to USD 24.02 billion in 2031, at a CAGR of 7.3%.

Microencapsulation Market Size & Forecast

- Market Size Available for Years: 2022–2031

- 2026 Market Size: USD 16.90 billion

- 2031 Projected Market Size: USD 24.02 billion

- CAGR (2026–2031): 7.3%

Microencapsulation Market Trends & Insights:

- The microencapsulation market is driven by the growing need to improve the stability, protection, controlled release, and functionality of sensitive ingredients across pharmaceutical, food & beverage, household & personal care, agricultural, textile, and other applications. Rising demand for functional and fortified products, controlled-release formulations, and ingredients with improved shelf stability is driving adoption of microencapsulation technologies. The market also benefits from encapsulation, which protects active ingredients from moisture, oxygen, light, and temperature during processing and storage. Furthermore, advances in encapsulation materials and processing technologies are improving delivery performance, formulation flexibility, and scalability, while ongoing product development across diverse industries is supporting market growth.

- By end-use Industry, the pharmaceuticals segment is estimated to dominate the market with a share of 52.5% in 2026.

- By shell material, polymers are expected to dominate the microencapsulation market.

- By technology, the emulsion technologies segment is expected to witness the fastest growth in the microencapsulation market from 2026 to 2031.

- By core material form, solid accounted for the largest share of 73% of the microencapsulation market in 2026.

- By Core Material, Active Ingredients are projected to account for the largest share of the microencapsulation market during the forecast period.

- Asia Pacific is expected to be the fastest-growing region in the microencapsulation market, registering a CAGR of 8.4% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=83597438

The microencapsulation market is evolving as manufacturers increasingly use encapsulation technologies to improve ingredient stability, protection, controlled release, and ease of incorporation across food & beverages, pharmaceuticals, household & personal care, agriculture, and other industries. Microencapsulation enables sensitive core materials such as vitamins, minerals, probiotics, flavors, essential oils, bioactive compounds, and active pharmaceutical ingredients to be protected from environmental and processing conditions, including heat, moisture, oxygen, and light. At the same time, manufacturers are expanding encapsulation capabilities across spray, emulsion, coacervation, polymerization, extrusion, and other technologies to address different core materials, shell materials, and release requirements. The growing use of functional and fortified products further encourages incorporating encapsulated ingredients into a broader range of formulations. As demand grows, encapsulation efficiency, ingredient stability, controlled release, process scalability, and compatibility between core and shell materials are becoming increasingly important in the microencapsulation market. Advances in formulation and process design enable manufacturers to better protect and retain sensitive ingredients while producing encapsulated materials suitable for commercial-scale applications.

By core material, the active ingredients segment accounts for the largest share of the microencapsulation market.

The active ingredients segment accounts for a significant share of the microencapsulation market because encapsulation technologies protect sensitive compounds and maintain their stability during processing and storage. Active ingredients can be susceptible to moisture, oxygen, light, temperature, and other environmental conditions that affect their effectiveness. Microencapsulation provides a protective barrier around these materials, improving stability, compatibility, ingredient retention, and controlled release. Growing demand for products requiring enhanced functionality and controlled delivery is further supporting the use of active ingredients as core materials, particularly where protection and release performance are important.

By core material form, liquid is expected to dominate the microencapsulation market.

The dominance of liquid core materials is supported by the extensive use of microencapsulation to encapsulate oils, emulsions, flavors, essential oils, fragrances, and other liquid active compounds within protective shell materials. Encapsulation improves stability by protecting these materials from oxidation, evaporation, moisture, light, and other environmental factors while maintaining their functional properties during processing, storage, and end use. The technology also enables the incorporation of liquid ingredients into solid and liquid formulations while supporting controlled release and improved handling. These benefits make liquid core materials widely utilized across food & beverages, pharmaceuticals, household & personal care, agriculture, and other industrial applications. The broad use of liquid ingredients in commercial formulations, along with microencapsulation's ability to enhance their stability, delivery, and performance, continues to support the liquid segment's leading position in the market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=83597438

North America is expected to dominate the microencapsulation market, accounting for the largest share.

North America accounts for a significant share of the microencapsulation market because the food & beverage, pharmaceutical, household & personal care, and agricultural industries extensively use microencapsulation technologies to enhance ingredient stability, functionality, and delivery performance. The region benefits from a well-established manufacturing base, advanced R&D capabilities, and a high concentration of companies involved in specialty ingredients, encapsulation technologies, and formulated products. Microencapsulation is widely used across applications involving flavors, fragrances, vitamins, minerals, bioactive compounds, active ingredients, and agricultural inputs, supporting demand across multiple end-use industries. The widespread adoption of functional foods, nutraceuticals, advanced pharmaceutical formulations, premium personal care products, and controlled-release agricultural products continues to support the use of microencapsulation in the region. In addition, ongoing investments in ingredient innovation, formulation technologies, and value-added products are increasing the use of microencapsulation to improve product stability, shelf life, sensory performance, and controlled-release characteristics. Major market participants, strong technological capabilities, and sustained demand for high-performance products continue to support North America's position in the microencapsulation market.

Top Companies in the Microencapsulation Market

The report profiles key players such as BASF SE (Germany), DSM-Firmenich (Switzerland), International Flavors & Fragrances Inc. (US), Givaudan (Switzerland), Cargill, Incorporated (US), Ingredion (US), Symrise (Germany), DuPont (US), Glanbia PLC (Ireland), Lycored (US), TasteTech (UK), Clextral (France), Vitae Naturals (Spain), Vitablend (Netherlands), and FrieslandCampina (Netherlands), among others.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=83597438

Investment Funding Context

Investment activity in the microencapsulation market is increasingly focused on expanding production capacity and strengthening encapsulation capabilities across food, fragrance, and other applications. In August 2025, DSM-Firmenich announced an investment of approximately EUR 55 million (~USD 64 million) in a 56,000-square-meter greenfield Taste manufacturing plant in Vadodara, Gujarat, India, incorporating encapsulation systems and expected to become operational in Q4 2027. In September 2024, DSM-Firmenich also invested close to S$ 30 million (~USD 23 million) in two new facilities in Singapore, including the Perfumery Automated Compounding Encapsulation (PEACE) Facility. In December 2025, Balchem announced a USD 25 million investment to build a state-of-the-art microencapsulation manufacturing facility in Orange County, New York, expected to open in 2027.

Revenue Shift Context

The global microencapsulation market is shifting toward advanced delivery, protection, and controlled-release solutions across pharmaceuticals, food & beverages, household & personal care, agriculture, textile, and building & construction applications. The market is projected to grow from USD 16.90 billion in 2026 to USD 24.02 billion by 2031, at a CAGR of 7.3%, supported by growing demand for improved ingredient stability, controlled release, taste masking, extended shelf life, and targeted delivery. Pharmaceuticals represent a major demand base, where microencapsulation is used for controlled-release and drug-delivery applications, while adoption is also expanding across food and beverages for protecting sensitive ingredients and improving formulation stability. Growing use in agricultural inputs, personal care formulations, textiles, and construction materials is further broadening the application base, while advances in encapsulation technologies and shell materials support the development of application-specific formulations.

Mergers and Acquisitions

Key players have pursued acquisitions and strategic investments to strengthen their microencapsulation and related ingredient capabilities.